A Phase II Study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS With High-risk ER+/HER2- Early Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Palbociclib (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Paclitaxel
- Indications Early breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms APPALACHES
- 23 Jul 2019 Planned End Date changed from 7 May 2031 to 13 Jun 2031.
- 23 Jul 2019 Planned primary completion date changed from 7 May 2024 to 13 Jun 2024.
- 20 Jun 2019 Status changed from not yet recruiting to recruiting.